Brazilian Real-Life Experience of Multiple Myeloma (MMyBRAve): Improvement in Outcomes, But Remaining Diagnostic and Therapeutic Gaps.

Autor: Hungria V; Clínica São Germano, São Paulo, Brazil. Electronic address: hungria@dialdata.com.br., Bittencourt RI; Hospital de Clínicas of Porto Alegre (HCPA), Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil., Martinez GA; Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil., Santos JA; CEHON - Centro de Hematologia e Oncologia da Bahia, Salvador, Brazil., de Almeida DR; Hospital São Vicente de Paulo, Passo Fundo, Brazil., Figueiredo VLP; Hospital do Servidor Público de São Paulo, São Paulo, Brazil., de Farias DLC; Hospital das Clínicas, Universidade Federal de Goiás, Goiania, Brazil., Zanella KR; CEPON - Centro de Pesquisas Oncológicas, Florianópolis, Brazil., Muniz LB; Casa de Saúde Santa Marcelina, São Paulo, Brazil., Senra JT; Medical Affairs, Takeda Pharmaceuticals Brazil, São Paulo, Brazil., Abreu RM; Medical Affairs, Takeda Pharmaceuticals Brazil, São Paulo, Brazil., Mattos ÉR; Centro de Ensino e Pesquisas, Fundação Dr. Amaral Carvalho, Jaú, Brazil.
Jazyk: angličtina
Zdroj: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2025 Jan; Vol. 25 (1), pp. 26-31. Date of Electronic Publication: 2024 Oct 09.
DOI: 10.1016/j.clml.2024.10.002
Abstrakt: Background: This study aimed at describing the demographic and clinical characteristics, treatment patterns and overall survival of patients with MM in Brazil to identify gaps in the disease diagnosis and treatment.
Methods: MMyBRAve (NCT03506386) was a multicenter, observational study of patients diagnosed with MM in Brazil between January 2008 and December 2016, with data collection between August 2018 and September 2019 at 17 participating centers.
Results: Of 943 patients included, 914 had complete data for overall survival (OS) analysis. The most used frontline regimens were cyclophosphamide, thalidomide and dexamethasone; bortezomib, cyclophosphamide and dexamethasone; and thalidomide and dexamethasone. After a median follow-up of 63 months, the median OS from diagnosis was 70 months. These results indicate continuous improvements in comparison with previous observational studies from Brazil. The median OS in transplantation-ineligible (N = 491) and eligible (N = 452) patients were 49 and 93 months, respectively (hazard ratio [HR] = 0.52; 95% confidence interval [CI], 0.43 to 0.63; P < .001). The median OS also differed between patients with and without known prognostic factors.
Conclusion: Despite the improvements, our results suggest that access to novel agents and transplantation continue to hinder further progress in patient outcomes in Brazil and countries with similar health-care constraints.
Competing Interests: Disclosure V. HUNGRIA and D.L.C. FARIAS received honoraria as speaker from Takeda. V. HUNGRIA and R. BITTENCOURT received honoraria for advisory committee from Takeda. G. MARTINEZ, J.A. SANTOS, D.R. ALMEIDA, V.L.P. FIGUEIREDO, K.R. ZANELLA, L.B. MUNIZ and E.R. MATTOS don´t have any disclosure. J.T. SENRA and R.M. ABREU are Takeda Pharmaceuticals, Brazil-São Paulo-SP employees.
(Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: